Vol. 1 No. 7 (2025), Articles
Vol. 1 No. 7 (2025)

GENETIC AND MOLECULAR NEUROSURGERY PROSPECTS IN BRAIN TUMORS

Articles
Published 2025-09-10
Qurbonov Abdulaziz Abdurahmon o’g’li
Student of the Urgench branch of Tashkent Medical Academy.
Yusufov Azizbek Baxtiyor oʻgʻli
Student of the Urgench branch of Tashkent Medical Academy.
PDF

Keywords

Brain tumors, neurosurgery, genetics, molecular neurosurgery, biomarkers, precision medicine, gene therapy, targeted treatment, immunogenetics

Abstract

Brain tumors remain one of the most complex challenges in neurosurgery due to their heterogeneous nature, invasive growth, and high recurrence rates. Recent advances in genetics and molecular biology have paved the way for precision neurosurgery, allowing for targeted therapies and individualized treatment approaches. Genetic profiling, molecular biomarkers, and innovative therapeutic modalities such as gene editing, molecular inhibitors, and immunogenetic interventions are transforming the landscape of neurosurgical oncology. These developments offer the possibility of not only improving surgical precision but also enhancing survival outcomes and quality of life in patients with brain tumors. This paper discusses the current progress and future prospects of genetic and molecular neurosurgery in the treatment of brain tumors.

PDF

References

1. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., … Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathologica, 131(6), 803–820. https://doi.org/10.1007/s00401-016-1545-1

2. Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., … Hayes, D. N. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020

3. Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H. J. (2006). Fluorescence-guided surgery with 5-ALA for resection of malignant glioma: A randomized controlled multicenter phase III trial. The Lancet Oncology, 7(5), 392–401. https://doi.org/10.1016/S1470-2045(06)70665-9

4. Jones, C., & Karajannis, M. A. (2017). Molecular-targeted therapy in neuro-oncology: Current strategies and future directions. Frontiers in Oncology, 7, 161. https://doi.org/10.3389/fonc.2017.00161

5. Friedmann-Morvinski, D., & Verma, I. M. (2014). Dedifferentiation and reprogramming: Origins of cancer stem cells. EMBO Reports, 15(5), 520–531. https://doi.org/10.15252/embr.201438186